Answers are grounded in this paper and cite their sources.
Epilepsy affects approximately 50 million individuals globally, with nearly 30% exhibiting refractory symptoms despite advances in antiseizure medications. There is an urgent need for adjunctive therapies that target underlying pathophysiological mechanisms such as oxidative stress and neuronal hyperexcitability. This review evaluates melatonin’s therapeutic potential in epilepsy management by synthesizing evidence from preclinical models, clinical trials, and mechanistic studies. Melatonin demonstrates pleiotropic anticonvulsant properties mediated through MT1/MT2 receptor-dependent and independent pathways. Key mechanisms include potent antioxidant activity via ROS scavenging, glutathione homeostasis, and Nrf2 pathway activation. It also exerts anti-inflammatory effects by suppressing NF-κB and modulating microglial polarization, while restoring excitatory-inhibitory balance through enhanced GABAergic transmission and inhibition of glutamatergic excitotoxicity. Additional molecular targets include CREB phosphorylation, BDNF expression, and ROR-mediated regulation of circadian genes. Melatonin further preserves mitochondrial integrity and synchronizes circadian rhythms frequently disrupted in epileptogenesis. Preclinical studies consistently report reduced seizure severity and frequency across models including PTZ and kainic acid-induced epilepsy. Human clinical trials, though heterogeneous, indicate that adjunctive melatonin significantly ameliorates seizure severity and sleep disturbances in adults, with a favorable safety profile. Effects on seizure frequency remain inconsistent, particularly in pediatric cohorts with infantile spasms; meta-analytic data support improvements in severity and sleep latency without increased adverse events. In conclusion, melatonin represents a promising, safe, and accessible adjunctive therapy for epilepsy, especially for mitigating seizure severity and comorbid sleep disorders. Future research should prioritize large-scale multicenter randomized controlled trials to establish standardized dosing protocols, optimize administration timing, and identify patient subgroups most likely to benefit
No takes yet. Share an insight, caveat, or question.
Mahdi Mashhadi Akbar Boojar (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: